)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Level Bio
Level Bio (LEVBIO) investor relations material
Level Bio Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary22 Oct, 2026
Executive summary
Q3 revenue rose 28% YoY to 8,644 KSEK; comparable growth excluding CyberGene was 59%, while gross margin fell to 40%.
Techtum Lab drove growth; priorities include Nordic expansion, portfolio development and profitability.
Financial highlights
Q3 revenue was 8,644 KSEK vs 6,750 KSEK; excluding CyberGene’s prior-year contribution, sales were 8,644 KSEK vs 5,432 KSEK, up 59%.
Q3 gross profit was 3,415 KSEK vs 3,787 KSEK; operating loss was 310 KSEK vs 207 KSEK, and net loss was 348 KSEK vs 164 KSEK.
9M revenue rose 17% to 26,841 KSEK from 22,939 KSEK; growth was 31% excluding CyberGene. Gross profit was 12,452 KSEK.
9M operating loss narrowed to 652 KSEK from 2,599 KSEK; result after financial items was 5,684 KSEK vs a loss of 2,649 KSEK, impacted by the disposal.
Q3 cash flow was -11 KSEK vs +16 KSEK YoY; 9M cash flow was -2,418 KSEK vs +496 KSEK.
Outlook and guidance
Strategy centers on Techtum Lab as a platform for profitable growth, growing distribution sales and reaching profitability.
Plans include establishing local presence across Nordic countries through hiring and/or acquisitions, and expanding sales in all Nordic markets.
Q4 priorities are sales execution, Nordic expansion and profitability; portfolio and pricing decisions will balance growth with margin.
CyberGene’s divestment creates comparison effects expected to persist through Q1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Level Bio
- Q2 2026 saw 10% sales growth and a major capital gain from the CyberGene divestment.LEVBIO
Q2 2026 - 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution.LEVBIOQ1 2026
- 29% revenue growth and CyberGene sale mark a strategic shift to Nordic lab distribution.LEVBIOQ4 2025
- Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion.LEVBIOQ3 2025
- Strong revenue growth, improved margins, and positive cash flow signal ongoing turnaround.LEVBIOQ2 2025
- Flat sales but improved results and cash flow signal operational progress and future growth.LEVBIOQ3 2024
- Q2 sales grew 10% year-over-year, with H2 growth expected from new products.LEVBIOQ2 2024
- Strong 42% revenue growth and positive cash flow signal operational turnaround.LEVBIOQ1 2025
- Q4 revenue up 22% and gross margin at 58%, with recurring sales driving future growth.LEVBIOQ4 2024
Next Level Bio earnings date
Q4 202618 Feb, 2027
Level Bio
Next Level Bio earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Level Bio is a biotechnology company focused on the development of innovative solutions in the life sciences sector. The company engages in research and product development aimed at addressing challenges in healthcare, leveraging advanced technologies and scientific expertise. Level Bio serves industries such as pharmaceuticals, diagnostics, and medical research with applications designed to improve patient care and treatment outcomes. The company is headquartered in Lund, Sweden, and its shares are listed on the Spotlight Stock Market.